GRACELL BIOTECHNOLOGIES-ADR (GRCL)
US38406L1035 - ADR
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -607.51M | -451.75M | -211.90M | -138.66M | -60.79M | |||
| Depreciation Amortization | 58.77M | 44.87M | 21.59M | 5.12M | 2.99M | |||
| Change In Working Capital | 15.08M | 25.26M | -10.75M | 700.00K | -4.06M | |||
| Interest Paid | 6.74M | 5.06M | 2.16M | N/A | N/A | |||
| Other non cash items | 51.01M | 77.08M | 2.91M | -2.56M | 0.00 | |||
| OPERATING CASH FLOW | -482.65M | -304.55M | -198.15M | -135.39M | -61.86M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -48.39M | -56.74M | -79.40M | -56.43M | -11.36M | |||
| Other Investing Activity | 60.00K | 15.13M | -14.54M | 97.80M | -102.00M | |||
| INVESTING CASH FLOW | -48.33M | -41.62M | -93.94M | 41.37M | -113.36M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | 36.12M | 19.94M | -35.81M | 0.00 | 138.70M | |||
| Stock Issued/Repurchased | 340.00K | 1.45B | 795.42M | 394.80M | 0.00 | |||
| Other Financing Activity | -3.14M | -14.46M | -3.14M | N/A | N/A | |||
| FINANCING CASH FLOW | 33.32M | 1.46B | 756.47M | 394.80M | 138.70M | |||
| Exchange Rate Effect | 123.30M | -35.32M | -22.13M | -600.00K | 0.00 | |||
| CHANGE IN CASH | -374.36M | 1.07B | 442.25M | 300.18M | -36.52M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -482.65M | -304.55M | -198.15M | -135.39M | -61.86M | |||
| Capital Expenditure | -48.39M | -56.74M | -79.40M | -56.43M | -11.36M | |||
| FREE CASH FLOW | -531.04M | -361.29M | -277.55M | -191.82M | -73.22M | |||
All data in CNY